**14.2** GLYCINE WITH CARBOHYDRATE, glycine with carbohydrate containing 500 mg L-glycine oral liquid: powder for, 30 x 4 g sachets, Glycine500®, Vitaflo Australia Pty Ltd

1. **Purpose of application**
   1. The submission requests a Restricted benefit listing for the dietary management of isovaleric acidaemia (IVA).
2. **Requested listing**

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| Name, Restriction,  Manner of administration  and form | | Max.  Qty | №.of  Rpts | Proprietary Name and Manufacturer | |
| GLYCINE WITH CARBOHYDRATE  glycine with carbohydrate, containing 500 mg L-Glycine oral liquid: powder for, 30 x 4 g sachets | | 4 | 5 | Glycine 500® | VF |
| **Condition/Indication:** | Isovaleric acidaemia | | | | |
| **Restriction:** | Restricted benefit | | | | |

* 1. The proposed price of Glycine500® is comparable with the price of other individual amino acid supplements with carbohydrate listed on the PBS (Phenylalanine 50, Valine 50 and Isoleucine 1000). The submission requested identical listing conditions (price, quantity and number of repeats) to these currently available products. The PBAC considered that this was appropriate.

1. **PBAC Outcome**
   1. The PBAC noted that the Nutritional Products Working Party supported the listing of Glycine500®. The PBAC recommend listing as requested in the submission.
2. **Context for Decision**

The PBAC helps decide whether and, if so, how medicines should be subsidised in Australia. It considers submissions in this context. A PBAC decision not to recommend listing or not to recommend changing a listing does not represent a final PBAC view about the merits of the medicine. A company can resubmit to the PBAC or seek independent review of the PBAC decision.

1. **Sponsor’s Comment**

The sponsor had no comment.